Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, 48-week, Open-label Extension Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis.

NCT03230292 is registered in ClinicalTrials.gov with UCB Biopharma SRL as lead sponsor.

NCT NCT03230292
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03230292 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, 48-week, Open-label Extension Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis.
Lead sponsor
UCB Biopharma SRL
Phase
Phase 2
Overall status
Completed
Start date
July 3, 2017
Completion date
March 6, 2019
Enrollment
43 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

chronic plaque psoriasis